Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Primary Angioplasty Compared With Thrombolytic Therapy for Acute Myocardial Infarction

Primary Angioplasty Compared With Thrombolytic Therapy for Acute Myocardial Infarction In this issue of The Journal, Weaver and colleagues1 provide a careful quantitative review of the available data from randomized trials comparing primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy in patients with acute myocardial infarction. This analysis of 10 trials includes 2606 patients and reports a reduction in mortality (odds ratio, 0.66; 95% confidence interval [CI], 0.46-0.94), in the composite of mortality and reinfarction (odds ratio, 0.58; 95% CI, 0.44-0.76), and in stroke (odds ratio, 0.35; 95% CI, 0.14-0.77) with the use of PTCA. However, before the data from these analyses are considered persuasive enough to conclusively establish the superiority of primary PTCA over thrombolytic therapy, 3 key questions must be addressed. See also p 2093. First, are there potential biases that could have inflated the results of the individual trials or this meta-analysis? Several potential biases both within each trial and in the authors' metaanalysis should http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Primary Angioplasty Compared With Thrombolytic Therapy for Acute Myocardial Infarction

Yusuf, Salim; Pogue, Janice
JAMA , Volume 278 (23) – Dec 17, 1997
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/primary-angioplasty-compared-with-thrombolytic-therapy-for-acute-npGPuNUxlp

References (12)

Publisher
American Medical Association
Copyright
Copyright © 1997 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1997.03550230086044
Publisher site
See Article on Publisher Site

Abstract

In this issue of The Journal, Weaver and colleagues1 provide a careful quantitative review of the available data from randomized trials comparing primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy in patients with acute myocardial infarction. This analysis of 10 trials includes 2606 patients and reports a reduction in mortality (odds ratio, 0.66; 95% confidence interval [CI], 0.46-0.94), in the composite of mortality and reinfarction (odds ratio, 0.58; 95% CI, 0.44-0.76), and in stroke (odds ratio, 0.35; 95% CI, 0.14-0.77) with the use of PTCA. However, before the data from these analyses are considered persuasive enough to conclusively establish the superiority of primary PTCA over thrombolytic therapy, 3 key questions must be addressed. See also p 2093. First, are there potential biases that could have inflated the results of the individual trials or this meta-analysis? Several potential biases both within each trial and in the authors' metaanalysis should

Journal

JAMA – American Medical Association

Published: Dec 17, 1997

There are no references for this article.